Monoclonal antibodies: Pharmacological relevance

被引:4
作者
Kaur, Jasleen [1 ]
Badyal, O. K. [1 ]
Khosla, P. P. [1 ]
机构
[1] Christian Med Coll & Hosp, Dept Pharmacol, Ludhiana, Punjab, India
关键词
antibodies; biological response modifiers; cancer chemotherapy; immunosuppressant; immunotherapeutics;
D O I
10.4103/0253-7613.30755
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Monoclonal antibodies (MAbs), a new class of biological agents, are used these days in therapeutics and diagnosis. MAbs also labeled as 'magic bullets', are highly specific antibodies produced by a clone of single hybrid cells formed in the laboratory by fusion of B cell with the tumor cell. The hybridoma formed yields higher amount of MAbs. MAbs can be produced in vitro and in vivo. Animals are utilized to produce MAbs, but these antibodies are associated with immunogenic and ethical problems. Of late, recombinant DNA technology, genetic engineering,phage display and transgenic animals are used to produce humanized MAbs or pure human MAbs, which have fewer adverse effects. MAbs alone or conjugated with drugs, toxins, or radioactive atoms are used for treatment of cancer, autoimmune disorders, graft rejections, infectious diseases, asthma, and various cardiovascular disorders. New MAbs are being developed which are more specific and less toxic.
引用
收藏
页码:5 / 14
页数:10
相关论文
共 79 条
  • [61] Simoons ML, 1997, LANCET, V349, P1429
  • [62] A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
    Targan, SR
    Hanauer, SB
    vanDeventer, SJH
    Mayer, L
    Present, DH
    Braakman, T
    DeWoody, KL
    Schaible, TF
    Rutgeerts, PJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (15) : 1029 - 1035
  • [63] Topol EJ, 1997, NEW ENGL J MED, V336, P1689
  • [64] The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders
    Treon, SP
    Anderson, KC
    [J]. SEMINARS IN ONCOLOGY, 2000, 27 (06) : 79 - 85
  • [65] Immune cell signaling defects in lupus: activation, anergy and death
    Tsokos, GC
    Liossis, SNC
    [J]. IMMUNOLOGY TODAY, 1999, 20 (03): : 119 - 124
  • [66] B cells, be gone - B-cell depletion in the treatment of rheumatoid arthritis
    Tsokos, GC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (25) : 2546 - 2548
  • [67] Tumour necrosis factor and Crohn's disease
    VanDeventer, SJH
    [J]. GUT, 1997, 40 (04) : 443 - 448
  • [68] VANLAAN S, 2006, NOMENCLATURE BIOL PR
  • [69] Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
    Vincenti, F
    Kirkman, R
    Light, S
    Bumgardner, G
    Pescovitz, M
    Halloran, P
    Neylan, J
    Wilkinson, A
    Ekberg, H
    Gaston, R
    Backman, L
    Burdick, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (03) : 161 - 165
  • [70] Monoclonal antibody therapy for cancer
    von Mehren, M
    Adams, GP
    Weiner, LM
    [J]. ANNUAL REVIEW OF MEDICINE, 2003, 54 : 343 - 369